Protagenic Therapeutics Inc. announced that the Japanese Patent Office has granted Patent JP 7714571B on July 18, 2025. This patent, which will remain in effect until March 31, 2041, is a key asset in the company's pipeline. It covers a modified stilbenoid and provides exclusivity to specific compounds, formulations, and their medical use in the treatment of epilepsy and seizures. This grant follows a similar patent granted in the UK and marks a significant step in Protagenic Therapeutics' innovative development efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.